Publication:
Pegylatedd interferon alfa-2b monotherapy and pegylated interferon alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B

Simple item page
dc.contributor.authorsKaymakoglu, Sabahattin; Oguz, Dilek; Gur, Gurden; Gurel, Selim; Tankurt, Ethem; Ersoz, Galip; Ozenirler, Seren; Kalayci, Cem; Poturoglu, Sule; Cakaloglu, Yilmaz; Okten, Atilla
dc.date.accessioned2022-03-14T08:38:57Z
dc.date.accessioned2026-01-11T10:34:34Z
dc.date.available2022-03-14T08:38:57Z
dc.date.issued2007-08
dc.description.abstractForty-eight hepatitis B virus (HBV) E antigen-negative chronic hepatitis B patients received pegylated interferon alfa-2b either alone or with lamivudine for 48 weeks and were followed for an additional 24 weeks. At the end of follow-up, virological response rates (HBV DNA levels of < 400 copies/ml) were similar in the monotherapy (24%) and combination therapy (26%) groups.
dc.identifier.doi10.1128/AAC.00088-07
dc.identifier.issn0066-4804
dc.identifier.pubmed17517832
dc.identifier.urihttps://hdl.handle.net/11424/242091
dc.identifier.wosWOS:000248523700056
dc.language.isoeng
dc.publisherAMER SOC MICROBIOLOGY
dc.relation.ispartofANTIMICROBIAL AGENTS AND CHEMOTHERAPY
dc.rightsinfo:eu-repo/semantics/openAccess
dc.titlePegylatedd interferon alfa-2b monotherapy and pegylated interferon alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B
dc.typearticle
dspace.entity.typePublication
oaire.citation.endPage3022
oaire.citation.issue8
oaire.citation.startPage3020
oaire.citation.titleANTIMICROBIAL AGENTS AND CHEMOTHERAPY
oaire.citation.volume51

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
file.pdf
Size:
66.89 KB
Format:
Adobe Portable Document Format
Download

Collections

Araştırma Çıktıları